Position of the Transparency Council – Kerendia (finerenone)
At its meeting on 19 September 2022 the Transparency Council adopted position No. 90/2022 on the evaluation of the drug of Kerendia (finerenone) for the indication: treatment of patients with chronic kidney disease (stages 3 and 4, with albuminuria) associated with type 2 diabetes mellitus in adults treated with insulin.